Protein glycationin vivo: functional and structural effects on yeast enolase
Authors:
- Ricardo A. GomesRGRicardo A. Gomes
- Luís M. A. OliveiraLOLuís M. A. Oliveira
- Mariana SilvaMSMariana Silva
- Carla AscensoCACarla Ascenso
- Alexandre QuintasAlexandre Quintas
- Gonçalo CostaGCGonçalo Costa
- Ana V. CoelhoAna V. Coelho
- Marta Sousa SilvaMSMarta Sousa Silva
- António E. N. FerreiraAFAntónio E. N. Ferreira
- Ana Ponces FreireAFAna Ponces Freire
- Carlos CordeiroCCCarlos Cordeiro
- 26 November 2008
- journal article
- research article
- Published by Portland Press Ltd. in Biochemical Journal
- Vol. 416 (3) , 317-326
Abstract
Protein glycation is involved in structure and stability changes that impair protein functionality, which is associated with several human diseases, such as diabetes and amyloidotic neuropathies (Alzheimer's disease, Parkinson's disease and Andrade's syndrome). To understand the relationship of protein glycation with protein dysfunction, unfolding and β-fibre formation, numerous studies have been carried out in vitro. All of these previous experiments were conducted in non-physiological or pseudo-physiological conditions that bear little to no resemblance to what may happen in a living cell. In vivo, glycation occurs in a crowded and organized environment, where proteins are exposed to a steady-state of glycation agents, namely methylglyoxal, whereas in vitro, a bolus of a suitable glycation agent is added to diluted protein samples. In the present study, yeast was shown to be an ideal model to investigate glycation in vivo since it shows different glycation phenotypes and presents specific protein glycation targets. A comparison between in vivo glycated enolase and purified enolase glycated in vitro revealed marked differences. All effects regarding structure and stability changes were enhanced when the protein was glycated in vitro. The same applies to enzyme activity loss, dimer dissociation and unfolding. However, the major difference lies in the nature and location of specific advanced glycation end-products. In vivo, glycation appears to be a specific process, where the same residues are consistently modified in the same way, whereas in vitro several residues are modified with different advanced glycation end-products.Keywords
This publication has 49 references indexed in Scilit:
- Advanced glycation end-products (AGEs): involvement in aging and in neurodegenerative diseasesAmino Acids, 2007
- Yeast protein glycation in vivo by methylglyoxalThe FEBS Journal, 2006
- Effect of methylglyoxal modification and phosphorylation on the chaperone and anti‐apoptotic properties of heat shock protein 27Journal of Cellular Biochemistry, 2006
- Argpyrimidine, a methylglyoxal-derived advanced glycation end-product in familial amyloidotic polyneuropathyBiochemical Journal, 2005
- UCSF Chimera—A visualization system for exploratory research and analysisJournal of Computational Chemistry, 2004
- Enhancement of Chaperone Function of α-Crystallin by Methylglyoxal ModificationBiochemistry, 2003
- Thermal, chemical and chemothermal denaturation of yeast enolaseJournal of Spectroscopy, 2003
- A fast method to predict protein interaction sites from sequencesJournal of Molecular Biology, 2000
- Pharmacology of methylglyoxal: formation, modification of proteins and nucleic acids, and enzymatic detoxification-A role in pathogenesis and antiproliferative chemotherapyGeneral Pharmacology: The Vascular System, 1996
- Refined structure of yeast apo-enolase at 2.25 Å resolutionJournal of Molecular Biology, 1990